22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Foreign visitors taste the delicacies of Tianjin's ancient town
- China introduces a standard framework for humanoid and embodied intelligence
- CPPCC unveils agenda of the annual session
- Geologists brave rugged terrain in Yunnan prospecting mission
- Senior enterprise official facing probe
- China's anti-graft authorities reveal extent of year's work
